METHODS OF REDUCING PHOSPHATE ABSORPTION
First Claim
Patent Images
1. A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
- administering orally to the subject an IgY anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to Npt2B of SEQ ID NO;
1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.
9 Assignments
0 Petitions
Accused Products
Abstract
A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.
17 Citations
33 Claims
-
1. A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
administering orally to the subject an IgY anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to Npt2B of SEQ ID NO;
1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
9. A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to an epitope within amino acids 234-362 of SEQ ID NO;
1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.- View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17, 18)
-
19. A method of reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia, the method comprising the step of:
administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to an epitope within amino acids 429-485 of SEQ ID NO;
1 in an amount effective to reduce or maintain the serum phosphate concentration in the subject.- View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28)
-
29. A method of reducing side effects of vitamin D therapy in a human comprising the step of:
administering orally to the subject (a) a vitamin D compound and (b) an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody that binds to Npt2B of SEQ ID NO;
1 in an amount effective to reduce hyperphosphatemia induced by vitamin D therapy.- View Dependent Claims (30, 31, 32, 33)
Specification